The company’s president and head of research and development, Dr Maria Grazia Roncarolo, is leading the trial.

Tr1X awarded $8 million CIRM grant to support TRX103 phase 1/2a trial for graft-versus-host disease: San Diego Monday, April 7, 2025, 11:00 Hrs [IST] Tr1X, Inc. (Trix), a clinical ...

Previous studies on regulatory T-cell (Treg) reconstitution after allogeneic hematopoietic SCT (HSCT) have suggested that, within the GVHD process, imbalance between effector T cells and Tregs may ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

The first trial showed that it could increase levels of Treg cells thought to be involved ... in phase 1/2 trials in SLE and graft versus host disease (GvHD), Roche’s RG 7835, which is in ...

The company’s president and head of research and development, Dr Maria Grazia Roncarolo, is leading the trial.

an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 ...

an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million ...